Naturally Occurring Compounds Targeting Peroxisome Proliferator Receptors: Potential Molecular Mechanisms and Future Perspectives for Promoting Human Health
Source abstract
Abstract
Background: Peroxisome-proliferator-activated receptors (PPARs) constitute nuclear transcription factors controlling gene expression associated with cell growth and proliferation, diverse proteins, lipids, and glucose metabolism, being related to several other pathophysiological states such as metabolic disorders, atherogenesis, carcinogenesis, etc. The present survey aims to analyze the natural compounds that can act as agonists for the PPAR-α, PPAR-β/δ, and PPAR-γ system targeting, highlighting how the amazing biochemical diversity of natural compounds can yield new insights into this “hotspot” of the scientific field. Methods: A narrative review was performed by searching the recent international literature for the last two decades in the most authoritative scientific databases, like PubMed, Scopus, Web of Science, and Embase, using appropriate keywords. Results: Several natural compounds and/or their synthetic derivatives can act as ligands of PPARs, stimulating their transcriptional activity and enabling their use as preventive and/or therapeutic agents for several disease states, such as inflammation, oxidative stress, metabolic disturbances, atherogenesis, and carcinogenesis. Although synthetic compounds are increasingly used as drugs to manage health problems, serious side effects have been observed, while their natural analogues exhibit only few minor side effects. Conclusions: Further clinical studies on natural compounds such as ligands of PPARs and the evaluation of the related molecular mechanisms are needed to implement an effective strategy concerning the pharmaco-technology, food chemistry, and nutrition to introduce them as part of clinical and dietary practice.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Peroxisome Proliferator-Activated Receptors · Adipose Tissue and Metabolism · Biochemical Acid Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Nutritional Sciences and Dietetics, School of Health Sciences, International Hellenic University, 57400 Thessaloniki, Greece
424 General Military Hospital of Thessaloniki, 54621 Thessaloniki, Greece
Department of Food Science and Nutrition, School of Environment, University of Aegean, 81400 Lemnos, Greece
Second Department of Propedeutic Surgery, Medical School, University of Athens, 11527 Athens, Greece
References (100+)
Show source-provided references
1. Lamichane, S., Dahal Lamichane, B., and Kwon, S.M. (2018). Pivotal Roles of peroxisome proliferator-activated receptors (PPARs) and their signal cascade for cellular and whole-body energy homeostasis. Int. J. Mol. Sci., 19.10.3390/ijms19040949 ↗
2. Hong, F., Xu, P., and Zhai, Y. (2018). The opportunities and challenges of peroxisome proliferator-activated receptors ligands in clinical drug discovery and development. Int. J. Mol. Sci., 19.10.3390/ijms19082189 ↗
3. The potential of natural products for targeting PPARα10.1016/j.apsb.2017.05.005 ↗
4. Sharma, A., and Lee, H.J. (2021). Role of phytoconstituents as PPAR agonists: Implications for neurodegenerative disorders. Biomedicines, 9.10.3390/biomedicines9121914 ↗
5. Zhang, Y., Zhang, X.Y., Shi, S.R., Ma, C.N., Lin, Y., Song, W.G., and Guo, S.D. (2024). Natural products in atherosclerosis therapy by targeting PPARs: A review focusing on lipid metabolism and inflammation. Front. Cardiovasc. Med., 11.10.3389/fcvm.2024.1372055 ↗
6. Dietary regulation of peroxisome proliferator-activated receptors in metabolic syndrome10.1016/j.phymed.2023.154904 ↗
7. The impact of physicochemical and molecular properties in drug design: Navigation in the “drug-like” chemical space10.1007/978-3-319-08927-0_21 ↗
8. Present drug-likeness filters in medicinal chemistry during the hit and lead optimization process: How far can they be simplified?10.1016/j.drudis.2018.01.010 ↗
9. Lipophilicity and biomimetic properties to support drug discovery10.1080/17460441.2017.1344210 ↗
10. A consideration of PPAR-gamma ligands with respect to lipophilicity: Current trends and perspectives10.1517/13543784.16.4.413 ↗
11. International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors10.1124/pr.58.4.5 ↗
12. The need for physiologically relevant peroxisome proliferator-activated receptor-gamma (PPAR-γ) ligands10.2174/18715303113139990003 ↗
13. Natural products and analogs as preventive agents for metabolic syndrome via peroxisome proliferator-activated receptors: An overview10.1016/j.ejmech.2021.113535 ↗
14. The Mechanisms of Action of PPARs10.1146/annurev.med.53.082901.104018 ↗
15. An overview on biological mechanisms of PPARs10.1016/j.phrs.2004.07.012 ↗
16. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism10.1042/bst0301086 ↗
17. Hong, F., Pan, S., Guo, Y., Xu, P., and Zhai, Y. (2019). PPARs as Nuclear Receptors for Nutrient and Energy Metabolism. Molecules, 24.10.3390/molecules24142545 ↗
18. Impact of phytochemicals on PPAR receptors: Omplications for disease treatments10.1155/2022/4714914 ↗
19. PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation10.1016/j.bbadis.2011.02.014 ↗
20. d’Angelo, M., Castelli, V., Tupone, M.G., Catanesi, M., Antonosante, A., Dominguez-Benot, R., Ippoliti, R., Cimini, A.M., and Benedetti, E. (2019). Lifestyle and food habits impact on chronic diseases: Roles of PPARs. Int. J. Mol. Sci., 20.10.3390/ijms20215422 ↗
21. Retinoid X receptor: Cellular and biochemical roles of nuclear receptor with a focus on neuropathological involvement10.1007/s12035-021-02709-y ↗
22. Brunmeir, R., and Xu, F. (2018). Functional regulation of PPARs through post-translational modifications. Int. J. Mol. Sci., 19.10.3390/ijms19061738 ↗
23. Skoczyńska, A., Ołdakowska, M., Dobosz, A., Adamiec, R., Gritskevich, S., Jonkisz, A., Lebioda, A., Adamiec-Mroczek, J., Małodobra-Mazur, M., and Dobosz, T. (2024). PPARs in Clinical Experimental Medicine after 35 Years of Worldwide Scientific Investigations and Medical Experiments. Biomolecules, 14.10.3390/biom14070786 ↗
24. Molecular recognition of agonist and antagonist for peroxisome proliferator-activated receptor-α studied by molecular dynamics simulations10.3390/ijms15058743 ↗
25. Capelli, D., Cerchia, C., Montanari, R., Loiodice, F., Tortorella, P., Laghezza, A., Cervoni, L., Pochetti, G., and Lavecchia, A. (2016). Structural basis for PPAR partial or full activation revealed by a novel ligand binding mode. Sci. Rep., 6.10.1038/srep34792 ↗
26. Sun, C., Mao, S., Chen, S., Zhang, W., and Liu, C. (2021). PPARs-orchestrated metabolic homeostasis in the adipose tissue. Int. J. Mol. Sci., 22.10.3390/ijms22168974 ↗
27. Vázquez-Carrera, M., and Wahli’, W. (2022). PPARs as key mediators in the regulation of metabolism and inflammation. Int. J. Mol. Sci., 23.10.3390/ijms23095025 ↗
28. The integration of lipid-sensing and anti-inflammatory effects: How the PPARs play a role in metabolic balance10.1186/1478-1336-5-1 ↗
29. Zheng, Y., Shao, M., Zheng, Y., Sun, W., Qin, S., Sun, Z., Zhu, L., Guan, Y., Wang, Q., and Wang, Y. (2024). PPARs in atherosclerosis: The spatial and temporal features from mechanism to druggable targets. J. Adv. Res., in press.10.1016/j.jare.2024.03.020 ↗
30. D’Aniello, E., Amodeo, P., and Vitale, R.M. (2023). Marine natural and nature-inspired compounds targeting peroxisome proliferator activated receptors (PPARs). Mar. Drugs, 21.10.3390/md21020089 ↗
31. PPAR agonists for the treatment of neuroinflammatory diseases10.1016/j.tips.2023.11.004 ↗
32. Distinct but complementary contributions of PPAR isotypes to energy homeostasis10.1172/JCI88894 ↗
33. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors10.1073/pnas.241410198 ↗
34. Asymmetry in the PPARgamma/RXRalpha crystal structure reveals the molecular basis of heterodimerization among nuclear receptors10.1016/S1097-2765(00)80448-7 ↗
35. The role of various peroxisome proliferator-activated receptors and their ligands in clinical practice10.1002/jcp.25804 ↗
36. A Mathematical model of the liver circadian clock linking feeding and fasting cycles to clock function10.1016/j.celrep.2016.09.060 ↗
37. Muscle as a “mediator” of systemic metabolism10.1016/j.cmet.2014.12.021 ↗
38. Peroxisome proliferator-activated receptor agonists and antagonists: An updated patent review (2020–2023)10.1080/13543776.2024.2332661 ↗
39. Peroxisome proliferator-activated receptor agonists and antagonists: A patent review (2014–present)10.1080/13543776.2020.1703952 ↗
40. PPAR dual agonists: Are they opening Pandora’s Box?10.1016/j.phrs.2007.03.002 ↗
41. A Contemporary overview of PPARα/γ dual agonists for the management of diabetic dyslipidemia10.2174/1874467212666190111165015 ↗
42. A new insight into the treatment of diabetes by means of pan PPAR agonists10.1111/cbdd.14020 ↗
43. Su, J., Luo, Y., Hu, S., Tang, L., and Ouyang, S. (2023). Advances in Research on Type 2 Diabetes Mellitus Targets and Therapeutic Agents. Int. J. Mol. Sci., 24.10.3390/ijms241713381 ↗
44. Gomes-Copeland, K.K.P., Meireles, C.G., Gomes, J.V.D., Torres, A.G., Sinoti, S.B.P., Fonseca-Bazzo, Y.M., Magalhães, P.O., Fagg, C.W., Simeoni, L.A., and Silveira, D. (2022). Hippeastrum stapfianum (Kraenzl.) R.S.Oliveira & Dutilh (Amaryllidaceae) ethanol extract activity on acetylcholinesterase and PPAR-α/γ receptors. Plants, 11.10.3390/plants11223179 ↗
45. Carneiro, A.A., Sinoti, S.B.P., de Freitas, M.M., Simeoni, L.A., Fagg, C.W., Magalhães, P.O., Silveira, D., and Fonseca-Bazzo, Y.M. (2022). Hydroethanolic Extract of Morus nigra L. Leaves: A dual PPAR-α/γ agonist with anti-inflammatory properties in lipopolysaccharide-stimulated RAW 264.7. Plants, 11.10.3390/plants11223147 ↗
46. Asperosaponin VI ameliorates the CMS-induced depressive-like behaviors by inducing a neuroprotective microglial phenotype in hippocampus via PPAR-γ pathway10.1186/s12974-022-02478-y ↗
47. Methoxyeugenol deactivates hepatic stellate cells and attenuates liver fibrosis and inflammation through a PPAR-ɣ and NF-kB mechanism10.1016/j.jep.2021.114433 ↗
48. Thymoquinone: An edible redox-active quinone for the pharmacotherapy of neurodegenerative conditions and glial brain tumors. A short review10.1016/j.biopha.2016.07.018 ↗
49. Antidiabetic activity of Nigella sativa (Black Seeds) and its active constituent (thymoquinone): A review of human and experimental animal studies10.4068/cmj.2021.57.3.169 ↗
50. Venkataraman, B., Almarzooqi, S., Raj, V., Alhassani, A.T., Alhassani, A.S., Ahmed, K.J., Subramanian, V.S., Ojha, S.K., Attoub, S., and Adrian, T.E. (2021). Thymoquinone, a dietary bioactive compound, exerts anti-inflammatory effects in colitis by stimulating expression of the colonic epithelial PPAR-γ transcription factor. Nutrients, 13.10.3390/nu13041343 ↗
51. Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: A hypothetical therapeutic for cytokine storm in COVID-19?10.1016/j.mce.2020.111095 ↗
52. Bernardo, A., Plumitallo, C., De Nuccio, C., Visentin, S., and Minghetti, L. (2021). Curcumin promotes oligodendrocyte differentiation and their protection against TNF-α through the activation of the nuclear receptor PPAR-γ. Sci. Rep., 11.10.1038/s41598-021-83938-y ↗
53. Colson, C., Batrow, P.L., Gautier, N., Rochet, N., Ailhaud, G., Peiretti, F., and Amri, E.Z. (2020). The Rosmarinus bioactive compound carnosic acid is a novel PPAR antagonist that inhibits the browning of white adipocytes. Cells, 9.10.3390/cells9112433 ↗
54. Wogonin accelerates hematoma clearance and improves neurological outcome via the PPAR-γ pathway after intracerebral hemorrhage10.1007/s12975-020-00842-9 ↗
55. PPAR-Gamma as putative gene target involved in Butein mediated anti-diabetic effect10.1007/s11033-020-05605-1 ↗
56. Potential of the chlorogenic acid as multitarget agent: Insulin-secretagogue and PPAR α/γ dual agonist10.1016/j.biopha.2017.07.086 ↗
57. Chlorogenic acid exhibits cholesterol lowering and fatty liver attenuating properties by up-regulating the gene expression of PPAR-α in hypercholesterolemic rats induced with a high-cholesterol diet10.1002/ptr.4751 ↗
58. Xie, Z., Gao, G., Wang, H., Li, E., Yuan, Y., Xu, J., Zhang, Z., Wang, P., Fu, Y., and Zeng, H. (2020). Dehydroabietic acid alleviates high fat diet-induced insulin resistance and hepatic steatosis through dual activation of PPAR-γ and PPAR-α. Biomed. Pharmacother., 127.10.1016/j.biopha.2020.110155 ↗
59. Guo, L., Kang, J.S., Kang, N.J., Je, B.I., Lee, Y.J., Park, Y.H., and Choi, Y.W. (2020). Pelargonidin suppresses adipogenesis in 3T3-L1 cells through inhibition of PPAR-γ signaling pathway. Arch. Biochem. Biophys., 686.10.1016/j.abb.2020.108365 ↗
60. Xie, Z., Zhao, J., Wang, H., Jiang, Y., Yang, Q., Fu, Y., Zeng, H., Hölscher, C., Xu, J., and Zhang, Z. (2020). Magnolol alleviates Alzheimer’s disease-like pathology in transgenic C. elegans by promoting microglia phagocytosis and the degradation of beta-amyloid through activation of PPAR-γ. Biomed. Pharmacother., 124.10.1016/j.biopha.2020.109886 ↗
61. Malva parviflora extract ameliorates the deleterious effects of a high fat diet on the cognitive deficit in a mouse model of Alzheimer’s disease by restoring microglial function via a PPAR-γ-dependent mechanism10.1186/s12974-019-1515-3 ↗
62. Asiatic acid prevents renal fibrosis in UUO rats via promoting the production of 15d-PGJ2, an endogenous ligand of PPAR-γ10.1038/s41401-019-0319-4 ↗
63. Biotin and chromium histidinate improve glucose metabolism and proteins expression levels of IRS-1, PPAR-γ, and NF-κB in exercise-trained rats10.1186/s12970-018-0249-4 ↗
64. Hesperetin derivative-14 alleviates inflammation by activating PPAR-γ in mice with CCl4-induced acute liver injury and LPS-treated RAW264.7 cells10.1016/j.toxlet.2017.04.008 ↗
65. Resveratrol prevents endothelial progenitor cells from senescence and reduces the oxidative reaction via PPAR-γ/HO-1 pathways10.3892/mmr.2016.5929 ↗
66. Huangkui capsule, an extract from Abelmoschus manihot (L.) medic, improves diabetic nephropathy via activating peroxisome proliferator-activated receptor (PPAR)-α/γ and attenuating endoplasmic reticulum stress in rats10.1016/j.jep.2016.05.033 ↗
67. Hyperin attenuates inflammation by activating PPAR-γ in mice with acute liver injury (ALI) and LPS-induced RAW264.7 cells10.1016/j.intimp.2015.10.017 ↗
68. The peroxisome proliferator-activated receptor (PPAR)-γ antagonist 2-chloro-5-nitro-N-phenylbenzamide (GW9662) triggers perilipin 2 expression via PPARδ and induces lipogenesis and triglyceride accumulation in human THP-1 macrophages10.1124/mol.119.117887 ↗
69. Polyisoprenoids: Structure, biosynthesis and function10.1016/j.plipres.2005.05.002 ↗
70. The chlorophyll-derived metabolite phytanic acid induces white adipocyte differentiation10.1038/sj.ijo.0802068 ↗
71. Phytanic acid activates the peroxisome proliferator-activated receptor α (PPARα) in sterol carrier protein 2-/sterol carrier protein x-deficient mice10.1074/jbc.274.5.2766 ↗
72. Phytanic acid: Production from phytol, its breakdown and role in human disease10.1007/s00018-005-5463-y ↗
73. A phytol-enriched diet induces changes in fatty acid metabolism in mice both via PPARalpha-dependent and -independent pathways10.1194/jlr.M400337-JLR200 ↗
74. Hydroxysafflor yellow A suppresses liver fibrosis induced by carbon tetrachloride with high-fat diet by regulating PPAR-γ/p38 MAPK signaling10.3109/13880209.2013.877491 ↗
75. Dual action of isoprenols from herbal medicines on both PPARgamma and PPARalpha in 3T3-L1 adipocytes and HepG2 hepatocytes10.1016/S0014-5793(02)02390-6 ↗
76. Various Terpenoids Derived from Herbal and Dietary Plants Function as PPAR Modulators and Regulate Carbohydrate and Lipid Metabolism10.1155/2010/483958 ↗
77. Oleanane-type triterpene saponins from the bark of Aralia elata and their NF-κB inhibition and PPAR activation signal pathway10.1016/j.bmcl.2011.08.024 ↗
78. An Anti-Inflammatory PPAR-γ Agonist from the Jellyfish-Derived Fungus Penicillium chrysogenum J08NF-410.1021/acs.jnatprod.7b00846 ↗
79. Food consumption and the incidence of type II diabetes mellitus10.1038/sj.ejcn.1602094 ↗
80. Citrus auraptene acts as an agonist for PPARs and enhances adiponectin production and MCP-1 reduction in 3T3-L1 adipocytes10.1016/j.bbrc.2007.11.119 ↗
81. Biosynthesis of the food and cosmetic plant pigment bixin (annatto)10.1126/science.1085162 ↗
82. Dietary supplementation with a natural carotenoid mixture decreases oxidative stress10.1038/sj.ejcn.1601655 ↗
83. Hypoglycaemic activity of Bixa orellana extract in the dog10.1358/mf.2008.30.4.1186073 ↗
84. Norbixin ingestion did not induce any detectable DNA breakage in liver and kidney but caused a considerable impairment in plasma glucose levels of rats and mice10.1016/S0955-2863(02)00177-8 ↗
85. Bixin regulates mRNA expression involved in adipogenesis and enhances insulin sensitivity in 3T3-L1 adipocytes through PPARgamma activation10.1016/j.bbrc.2009.10.162 ↗
86. Polychlorinated compounds with PPAR-gamma agonistic effect from the medicinal fungus Phellinus ribis10.1016/j.bmcl.2008.07.034 ↗
87. Loss of PPAR gamma in immune cells impairs the ability of abscisic acid to improve insulin sensitivity by suppressing monocyte chemoattractant protein-1 expression and macrophage infiltration into white adipose tissue10.1016/j.jnutbio.2007.02.010 ↗
88. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha10.1038/nature01921 ↗
89. Modulation of meal pattern in the rat by the anorexic lipid mediator oleoylethanolamide10.1038/sj.npp.1300166 ↗
90. An anorexic lipid mediator regulated by feeding10.1038/35102582 ↗
91. Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats10.1016/j.neuropharm.2005.02.013 ↗
92. Upregulation of PPAR-γ mediates the renoprotective effect of omega-3 PUFA and ferulic acid in gentamicin-intoxicated rats10.1016/j.biopha.2018.01.036 ↗
93. New ellagic acid derivative from the fruits of heat-tolerant plant Conocarpus lancifolius Engl. and their anti-inflammatory, cytotoxic, PPAR agonistic activities
94. Essential oil from Fructus Alpiniae zerumbet ameliorates vascular endothelial cell senescence in diabetes by regulating PPAR-γ signalling: A 4D label-free quantitative proteomics and network pharmacology study10.1016/j.jep.2023.117550 ↗
95. 18:0 Lyso PC, a natural product with potential PPAR-γ agonistic activity, plays hypoglycemic effect with lower liver toxicity and cardiotoxicity in db/db mice10.1016/j.bbrc.2021.09.059 ↗
96. Liberato, M.V., Nascimento, A.S., Ayers, S.D., Lin, J.Z., Cvoro, A., Silveira, R.L., Martínez, L., Souza, P.C., Saidemberg, D., and Deng, T. (2012). Medium chain fatty acids are selective peroxisome proliferator activated receptor (PPAR) γ activators and pan-PPAR partial agonists. PLoS ONE, 7.10.1371/journal.pone.0036297 ↗
97. Do sphingoid bases interact with the peroxisome proliferator activated receptor alpha (PPAR-alpha)?10.1016/S0898-6568(00)00092-9 ↗
98. Multimodal stepped care approach with acupuncture and PPAR-α agonist palmitoylethanolamide in the treatment of a patient with multiple sclerosis and central neuropathic pain10.1136/acupmed-2011-010119 ↗
99. Peroxisome proliferator-activated receptor agonists and bladder cancer: Lessons from animal studies10.1080/10590501.2012.735519 ↗
100. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a γ-dominant PPAR α/γ agonist: Lack of evidence for urolithiasis as an inciting event10.1177/0192623307311757 ↗